REG - BioVentix PLC - Posting of Annual Report and Notice of AGM

BioventixAnnouncement

10/11/2023 16:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231110:nRSJ1402Ta&default-theme=true

RNS Number : 1402T  BioVentix PLC  10 November 2023

 

 

Bioventix plc

("Bioventix" or the "Company")

 

Posting of Annual Report and Notice of AGM

 

Bioventix plc (AIM: BVXP), a UK company specialising in the development and
commercial supply of high-affinity monoclonal antibodies for applications in
clinical diagnostics, announces that it has today posted its Annual Report for
the year ended 30 June 2023 together with a Notice of Annual General Meeting
("AGM") and Form of Proxy to shareholders that have elected to receive
documentation in hard copy format. The documents will also be available from
the Company's website at www.bioventix.com (http://www.bioventix.com) under
the Investors section.

 

The Company's AGM will be held at Farnham Castle, Farnham, Surrey, GU9 0AG on
Thursday 7 December 2023 at 2.00pm.

For further information please contact:

 Bioventix plc                      Chief Executive Officer  Tel: 01252 728 001

Peter Harrison

 Cavendish Capital Markets Limited  Corporate Finance        Tel: 020 7220 0500

Geoff Nash/Simon Hicks
ECM

Nigel Birks/Harriet Ward

 

About Bioventix plc:

 

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAQBLFFXFLFFBK